Under the terms of the agreement, VGX will provide multiple batches of a Cystic fibrosis transmembrane conductance regulator (CFTR) product to support clinical studies planned to run through 2010. If all options are exercised, several hundred grams of plasmid DNA will be provided, making this agreement one of the largest contracts for non-viral gene therapy products ever undertaken.
Deborah Gill, Consortium’s lead investigator, said: “Our CpG-free product, utilizing technology developed by Cayla-InvivoGen, presented some unique challenges for large-scale production, but the Team at VGX used their vast expertise in producing non-viral products to meet our demanding timelines.”